Lymphocyte Activation Gene-3 Blocker
- Name
- Lymphocyte Activation Gene-3 Blocker
- Accession Number
- DBCAT005804
- Description
Not Available
- Drugs
Drug Drug Description Relatlimab A monoclonal antibody targeted against LAG-3 which is used in combination with nivolumab for the treatment of unresectable or metastatic melanoma. - Drugs & Drug Targets
Drug Target Type Relatlimab Lymphocyte activation gene 3 protein target